| Literature DB >> 20811313 |
Alice Ruth Foxwell1, Peter McIntyre, Helen Quinn, Katrina Roper, Mark S Clements.
Abstract
We estimated the potential benefits of advancing the first dose of pertussis vaccine for infants from 8 to 6 weeks of age, using Australian national disease databases. Infants had notification rates 3-fold greater than the general population and accounted for 52% of recorded hospitalizations. Infants 1 and 2 months of age had notification rates 3.5 times (95% CI: 2.7-4.5) higher than infants 3 to 11 months of age. Estimation of acceleration of the vaccine to 6 weeks of age reduced average notifications, hospitalizations, and hospital bed-days by 8%, 9%, and 12%, respectively, with larger reductions in an epidemic year.Entities:
Mesh:
Substances:
Year: 2011 PMID: 20811313 DOI: 10.1097/INF.0b013e3181f43906
Source DB: PubMed Journal: Pediatr Infect Dis J ISSN: 0891-3668 Impact factor: 2.129